Skip to content

Study · Non-randomized trial · n = 8 · 1995

4 results

The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.

Loche S, Cambiaso P, Merola B, Colao A, Faedda A, Imbimbo BP, Deghenghi R, Lombardi G, Cappa M

The Journal of clinical endocrinology and metabolism1 Sept 1995Cited by 19 (Europe PMC)

PMID7673411 (opens in a new tab)DOI10.1210/jcem.80.9.7673411 (opens in a new tab)PepBankPUB-07673411
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with idiopathic GH deficiency, the GH response to hexarelin was similar to that of short normal children.

    In plain wordsIn patients with idiopathic GH deficiency, hexarelin raised GH about as much as in short children with normal GH.

    Peptide
    Hexarelin
    Outcome
    No significant changeGH response to hexarelin in idiopathic GHD versus short normal children
    Study

    n = 8

    Comparator
    Short normal children
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    In patients with idiopathic GHD, the GH response to Hex was similar to that observed in short normal children, and it was significantly higher than the response to GHRH.
    2 context sentences
    Summary · context
    GHD was idiopathic in 8 patients and associated with pituitary stalk interruption syndrome in 8, with a pituitary cyst in 2, and with empty sella syndrome in 1.
    Summary · context
    We evaluated the GH response to maximal doses of Hex (2 micrograms/kg, iv) and GHRH-(1-29) (1 microgram/kg, iv) in 15 children (11 boys and 4 girls, aged 6.0-17.3 yr) and 4 adults (3 men and 1 woman, aged 20.2-30 yr) with GH deficiency (GHD).
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with idiopathic GH deficiency, hexarelin produced a significantly higher GH response than GHRH.

    In plain wordsIn patients with idiopathic GH deficiency, hexarelin raised GH more than GHRH did.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH response to hexarelin versus GHRH in idiopathic GHD
    Study

    n = 8

    Comparator
    GHRH 1 microgram/kg iv
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    In patients with idiopathic GHD, the GH response to Hex was similar to that observed in short normal children, and it was significantly higher than the response to GHRH.
    2 context sentences
    Summary · context
    GHD was idiopathic in 8 patients and associated with pituitary stalk interruption syndrome in 8, with a pituitary cyst in 2, and with empty sella syndrome in 1.
    Summary · context
    We evaluated the GH response to maximal doses of Hex (2 micrograms/kg, iv) and GHRH-(1-29) (1 microgram/kg, iv) in 15 children (11 boys and 4 girls, aged 6.0-17.3 yr) and 4 adults (3 men and 1 woman, aged 20.2-30 yr) with GH deficiency (GHD).
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with GH deficiency and hypothalamic-pituitary anatomical abnormalities, the GH response to hexarelin was absent or blunted, except in 1 patient with a pituitary cyst.

    In plain wordsIn patients with GH deficiency and pituitary structural problems, hexarelin raised GH little or not at all, except in one patient.

    Peptide
    Hexarelin
    Outcome
    DecreaseGH response to hexarelin in GHD with anatomical abnormalities
    Study

    n: not reported in source

    Comparator
    Short normal children and idiopathic GHD
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    In the patients with GHD associated with anatomical abnormalities, the GH responses to GHRH varied from normal to absent. Among these subjects, only 1 patient with a pituitary cyst had a sizable GH response to Hex, whereas in all others, the GH response to Hex was absent or blunted compared with tho…
    2 context sentences
    Summary · context
    GHD was idiopathic in 8 patients and associated with pituitary stalk interruption syndrome in 8, with a pituitary cyst in 2, and with empty sella syndrome in 1.
    Summary · context
    We evaluated the GH response to maximal doses of Hex (2 micrograms/kg, iv) and GHRH-(1-29) (1 microgram/kg, iv) in 15 children (11 boys and 4 girls, aged 6.0-17.3 yr) and 4 adults (3 men and 1 woman, aged 20.2-30 yr) with GH deficiency (GHD).
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with GH deficiency without ACTH deficiency, hexarelin caused a slight but significant rise in cortisol.

    In plain wordsIn patients with GH deficiency but no ACTH deficiency, hexarelin caused a small rise in cortisol.

    Peptide
    Hexarelin
    Outcome
    IncreaseCortisol response to hexarelin
    Study

    n: not reported in source

    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    In all patients except those with associated ACTH deficiency, Hex administration caused a slight, but significant, increase in cortisol concentrations.
    1 context sentence
    Summary · context
    We evaluated the GH response to maximal doses of Hex (2 micrograms/kg, iv) and GHRH-(1-29) (1 microgram/kg, iv) in 15 children (11 boys and 4 girls, aged 6.0-17.3 yr) and 4 adults (3 men and 1 woman, aged 20.2-30 yr) with GH deficiency (GHD).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.